Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Ying Wang, Jiang Cao, Weiying Gu...
https://pubmed.ncbi.nlm.nih.gov/35333600/Actively Recruiting
Led by Chinese PLA General Hospital · Updated on 2025-09-03
9
Participants Needed
1
Research Sites
121 weeks
Total Duration
Researchers are evaluating a new immune cell therapy called anti-BCMA-CD19 CAR-T cells in adults aged 18 to 75 years with IgG4-related disease IgG4-RD that has returned or not improved after standard treatments like glucocorticoids or rituximab. This Phase 2, open-label, single-arm study aims to assess the safety and preliminary effectiveness of this therapy by monitoring side effects and changes in disease activity scores at 12 and 26 weeks. IgG4-RD is a chronic disorder affecting multiple organs and sometimes resists conventional treatments, creating a need for new options. Participants will have their blood immune cells collected through leukapheresis, which are then modified outside the body to target disease-causing cells. Before receiving the therapy, they will get chemotherapy with cyclophosphamide and fludarabine for three days to prepare their immune system. On Day 0, participants will receive a single intravenous infusion of the anti-BCMA-CD19 CAR-T cells at one of three dose levels. After infusion, they will have safety and efficacy monitoring visits up to 52 weeks. Throughout the study, participants will attend regular clinic visits for safety evaluations, blood tests, and imaging to monitor treatment effects and side effects, including specific immune responses and cell counts. Researchers will assess dose-limiting toxicities within 28 days and changes in disease activity scores at 12 and 26 weeks. Secondary measures include monitoring the presence and activity of CAR-T cells, lesion size, and blood markers. Some participants may be followed for up to one year to better understand long-term effects.
CONDITIONS
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
Y
YIWEN WANG, M.D.
Y
YUFEI GUO, M.M.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Chinese PLA General Hospital
Lead Sponsor
Xuzhou Medical University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 1 to 2 weeks
Participants undergo leukapheresis to collect peripheral blood mononuclear cells, which are then modified and expanded in the lab to produce the CAR-T cells.
1 visit for leukapheresis
Duration - 3 days
Participants receive lymphodepletion chemotherapy with cyclophosphamide and fludarabine intravenously over 3 days to prepare the body for CAR-T cell infusion.
3 consecutive daily visits (in-person, IV chemotherapy)
Duration - Single day (Day 0)
Participants receive a single intravenous infusion of anti-BCMA-CD19 CAR-T cells at the assigned dose level.
1 infusion visit (in-person)
Duration - Up to 52 weeks
Participants are regularly monitored for safety, tolerability, and preliminary efficacy including adverse events and immune responses through Week 52.
Weekly visits for the first 4 weeks, then periodic visits up to Week 52
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Ying Wang, Jiang Cao, Weiying Gu...
https://pubmed.ncbi.nlm.nih.gov/35333600/Yong Zhang, Dan Liu, Zhouao Zhang...
https://pubmed.ncbi.nlm.nih.gov/38602546/Ming Shi, Jiaojiao Wang, Hongming Huang...
https://pubmed.ncbi.nlm.nih.gov/38643278/Yeting Sun, Sicheng Huang, Bo Zhang...
https://pubmed.ncbi.nlm.nih.gov/39672025/Chinese PLA General Hospital
Lead Sponsor
Xuzhou Medical University
Collaborating Sponsor